Key regions: Germany, United States, India, Japan, United Kingdom
The demand for Anti-Rheumatic Drugs in Togo is increasing steadily.
Customer preferences: Patients suffering from rheumatoid arthritis, osteoarthritis, and other rheumatic diseases are the primary consumers of Anti-Rheumatic Drugs in Togo. The preference for these drugs is driven by the need to alleviate pain and inflammation associated with these conditions. Patients tend to prefer drugs that provide fast relief with minimal side effects.
Trends in the market: The Anti-Rheumatic Drugs market in Togo is witnessing a shift towards biologic drugs. Biologic drugs are more effective in managing rheumatic diseases than traditional non-steroidal anti-inflammatory drugs (NSAIDs). The trend towards biologic drugs is driven by the need for more targeted and personalized treatment options. However, the high cost of biologic drugs remains a challenge for many patients in Togo.
Local special circumstances: Togo has a relatively small pharmaceutical industry, and most of the Anti-Rheumatic Drugs consumed in the country are imported. The lack of local production capacity makes the market vulnerable to supply chain disruptions and price fluctuations in the global market. Moreover, the high cost of these drugs makes them unaffordable for many patients, particularly those without health insurance coverage.
Underlying macroeconomic factors: The Togolese economy is heavily reliant on agriculture, which accounts for over 40% of the country's GDP. The low levels of industrialization and limited diversification of the economy limit the country's ability to generate foreign exchange and create employment opportunities. These factors contribute to the high levels of poverty and limited access to healthcare services in the country. The government's efforts to improve healthcare infrastructure and expand health insurance coverage are expected to increase access to Anti-Rheumatic Drugs and other essential medicines in the country. However, the high cost of these drugs remains a significant challenge for many patients.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
